As of July 21, 2022, HHS had distributed nearly 200,000 Jynneos vaccines to priority cities and accelerated the inspection of approximately 800,000 vaccines for delivery this summer while procuring millions more for delivery in mid-2023.
Over the coming days and weeks, HHS continued on July 21, 2022, it will continue to strengthen and accelerate its strategy on combatting monkeypox.
As U.S. FDA completes its review of the Bavarian Nordic facility, expected by the end of July 2022, HHS’ Strategic National Stockpile is preparing to quickly and efficiently distribute the approximate 786,000 doses that would come available.
- HHS continues to work with Bavarian Nordic to preposition those doses in the USA to be more available.
- HHS will expeditiously announce allocations of the 786,000 doses so U.S. jurisdictions can immediately make requests.
- Orders from states and jurisdictions for vaccines are delivered on average within 30 hours of being placed.
- HHS will seek additional data from jurisdictions regarding vaccine use data.
HHS has allocated vaccines to states and cities based on both the case burden and the size of the underlying population at the highest risk of severe disease and infection.
In its most recent vaccine allocation, HHS revised its formula to be more reflective of case burden, shifting from a 50% case burden and 50% at-risk model to a 75% case burden and 25% at-risk allocation to be most responsive to communities experiencing the most significant impacts of the outbreak.
As an example, approximately 26,000 additional Jynneos doses were delivered to New York City on July 21, 2022, as part of Phase 2b allocations.
According to the U.S. CDC’s outbreak report issued on July 22, 2022, New York City, Chicago, Washington DC, Los Angeles, and San Francisco have confirmed a large majority of the 2,891 monkeypox cases since May 2022.
And HHS confirmed it would continue to adapt the vaccine allocation strategy with each vaccine allocation and distribution phase.